Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

PURPOSE: Treatment of primary immunodeficiency diseases (PIDD) with subcutaneous (SC) infusions of IgG preceded by injection of recombinant human hyaluronidase (rHuPH20) (IGHy) to increase SC tissue permeability was evaluated in two consecutive, prospective, non-controlled, multi-center studies. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasserman, Richard L., Melamed, Isaac, Stein, Mark R., Engl, Werner, Sharkhawy, Marlies, Leibl, Heinz, Puck, Jennifer, Rubinstein, Arye, Kobrynski, Lisa, Gupta, Sudhir, Grant, Andrew J., Ratnayake, Anoshie, Richmond, Wendell G., Church, Joseph, Yel, Leman, Gelmont, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940441/
https://www.ncbi.nlm.nih.gov/pubmed/27220317
http://dx.doi.org/10.1007/s10875-016-0298-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940441/
https://www.ncbi.nlm.nih.gov/pubmed/27220317
http://dx.doi.org/10.1007/s10875-016-0298-x

Ejemplares similares